Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

JERUSALEM& TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 16, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a Phase 3, randomized,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials